New York, June 10, 2026, 17:04 EDT
- Outlook Therapeutics shares traded around $0.89, gaining about 26% from the previous close. Volume was high as investors watched the FDA review timing for Lytenava.
- Outlook Therapeutics, Inc. said its new U.S. resubmission is under a Class 1 review, with the FDA likely to make a decision in 60 days after receiving the file.
- The stock remains under $1, so Nasdaq compliance is still an issue and dilution risks are front and center.
Outlook Therapeutics shares surged Wednesday as the stock once again drew regulatory-timer trades after the company filed its newest FDA application for ONS-5010/LYTENAVA, its candidate for wet age-related macular degeneration. The stock was last quoted near $0.89, up about 26% from Tuesday’s close, with shares trading between $0.6853 and $0.8999 and volume near 21.9 million shares.
Investors are focused on timing. Outlook said June 1 it resubmitted its Biologics License Application, or BLA, for ONS-5010/LYTENAVA to the FDA. The drug targets neovascular age-related macular degeneration, or wet AMD, which affects central vision.
Outlook filed after a big turn in its FDA battle. The company said the FDA Office of New Drugs granted its appeal through Formal Dispute Resolution, finding “substantial evidence of effectiveness has been established” for Lytenava in wet AMD. The review will now count as a Class 1 resubmission, meaning a faster FDA review, and a PDUFA decision will come within 60 days of FDA receipt. PDUFA sets the target date for FDA drug-application decisions. Outlook Therapeutics, Inc.
The new timetable is different from late 2025, when Outlook was still facing another Complete Response Letter, or CRL. That’s the FDA’s way of telling a company its application can’t be approved as it stands. Back in December, Reuters said the agency had refused another approval for Lytenava and called for confirmatory efficacy data, after previous rejections tied to efficacy and manufacturing.
Outlook called the latest FDA review a labeling process, not a demand for more trials. The company said the FDA asked its Division of Ophthalmology and Office of Specialty Medicine to help with final product labeling. No new trials are needed, according to Outlook.
Chief Executive Bob Jahr said in the release the resubmission “represents the strength of our application and the tremendous dedication of our entire organization.” He added that Outlook was “encouraged with the Class 1 review designation.” Outlook Therapeutics, Inc.
The drug is an eye formulation of bevacizumab. Outlook says its bevacizumab-vikg blocks VEGF—vascular endothelial growth factor—a protein tied to unwanted blood vessel growth and leaking in the retina. Anti-VEGF therapies target that pathway.
Lytenava, if it gets the green light, would go up against current anti-VEGF drugs in the U.S. wet AMD space, including Roche’s Lucentis, Vabysmo, and Regeneron’s Eylea. Reuters has pointed to those as established approved options. Outlook is pitching Lytenava as potentially the first FDA-approved bevacizumab eye drug for retinal conditions.
Outlook says Lytenava is already cleared for sale in the EU and U.K. with European Commission and U.K. MHRA approvals for wet AMD. Commercial rollout is underway in Germany, Austria and the U.K., but pricing and reimbursement hurdles remain in some EU countries before sales start.
Outlook’s stock action is key since the company is facing a Nasdaq listing problem. It said it’s not meeting the $1 minimum bid standard right now. Outlook has until August 17, 2026, to get back in line, which means closing at $1 or above for 10 straight trading days.
July 16 is a key date for Outlook shareholders. The company has called a special meeting to vote on a reverse stock split proposal, which could be anywhere from 1-for-10 to 1-for-50. Shareholders will also consider boosting authorized common shares to 600 million from 260 million, and there’s another proposal for possible shares tied to warrants.
The risk for Outlook isn’t only about getting FDA approval. In its March-quarter filing, the company said it had $7.7 million in cash and cash equivalents as of March 31 and didn’t expect that—along with proceeds from an April offering—to cover 12 months of operations. It also raised substantial doubt about staying a going concern. More financing means possible shareholder dilution. A reverse split may not keep the stock up for long. And delays, negative labeling, or an FDA rejection could all weigh heavily on a company now so dependent on a single regulatory decision.
The setup is basic for now. Investors are eyeing whether Outlook can leverage an FDA appeal win into U.S. approval ahead of any Nasdaq compliance deadlines or a fresh financing, or before a reverse split resets the clock again.
